03 August 2018
Visiongain’ has launched a new pharma report Global Pharmacovigilance Market Forecast 2018-2028 : US, Japan, Germany, the UK, France, Italy, Spain, Brazil, Russia, India, China, South Korea, National Pharmacovigilance Systems, Leading Companies, Trends
This report covers trends in the pharmacovigilance market from 2017. It discusses those operations, regulations for drug monitoring, and the future of drug safety. It analyses pharmacovigilance from historical events to the future, predicting how post-marketing drug assessments will develop, and revenues from those services expand. National regulatory authorities are moving towards risk-benefit management planning to assess drug safety, putting greater pressure on pre-marketing safety and efficacy data. Needs for post-marketing surveillance have also increased, with active and intensive monitoring being introduced into adverse drug reaction reporting systems.
The lead analyst of the report commented “Using pharmacogenomics to establish safety profiles for drugs potentially represents the most significant steps in pharmacovigilance over the next decade. The number of clinical genetic tests being designed and produced is increasing, as is the volume of pharmacogenomic data submitted to regulators. As more is understood of the role of genetic variations in drug safety, regulators will demand more pharmacogenomic data during the approval application process for inclusion in risk management strategies.
The discovery and use of biomarkers, either during drug development or the early post-marketing phase, can accelerate drug approval or expansion of approval. New classification methods for adverse reactions will help to establish ADR mechanisms in relation to the genetic characteristic of the patient. This will, in a similar way to the discovery of biomarkers, help mark out subpopulations for whom the drug is an inappropriate. Further development of the system will eventually lead to its adoption as a common method of classification globally.”
Leading companies featured in the report include Accenture PLC, Cognizant Technology Solutions Corporation, Tata Consultancy Services (TCS), Capgemini SE, Tech Mahindra Limited, Infosys Limited (Infosys), Wipro Limited (Wipro), Oracle Corporation (Oracle), Bristol-Myers Squibb Company, HCL Technologies Ltd., Olympus Corporation
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.
11 May 2021
Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.
11 May 2021
The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.
06 May 2021
Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.